"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 2 | 2 | 4 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 7 | 1 | 8 |
| 2007 | 3 | 4 | 7 |
| 2008 | 11 | 2 | 13 |
| 2009 | 3 | 2 | 5 |
| 2010 | 5 | 2 | 7 |
| 2011 | 3 | 3 | 6 |
| 2012 | 3 | 2 | 5 |
| 2013 | 9 | 4 | 13 |
| 2014 | 5 | 4 | 9 |
| 2015 | 8 | 4 | 12 |
| 2016 | 1 | 2 | 3 |
| 2017 | 5 | 2 | 7 |
| 2018 | 2 | 6 | 8 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 7 | 8 |
| 2021 | 4 | 6 | 10 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 0 | 1 |
| 2024 | 4 | 4 | 8 |
| 2025 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. Oncologist. 2025 Jul 04; 30(7).
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord. 2025 Sep 15; 385:119366.
-
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025 Mar 17; 31(6):975-982.
-
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States. J Med Econ. 2025 Dec; 28(1):335-345.
-
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025 Mar-Apr; 75(2):141-167.